Page last updated: 2024-10-30
lamotrigine and Attention Deficit and Disruptive Behavioral Disorders
lamotrigine has been researched along with Attention Deficit and Disruptive Behavioral Disorders in 2 studies
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| " The authors wished to prospectively study the efficacy of lamotrigine as adjunctive or monotherapy in adolescents with bipolar disorder who were experiencing a depressive episode." | 5.12 | An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. ( Chang, K; Howe, M; Saxena, K, 2006) |
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Glauser, TA | 1 |
| Cnaan, A | 1 |
| Shinnar, S | 1 |
| Hirtz, DG | 1 |
| Dlugos, D | 1 |
| Masur, D | 1 |
| Clark, PO | 1 |
| Capparelli, EV | 1 |
| Adamson, PC | 1 |
| Chang, K | 1 |
| Saxena, K | 1 |
| Howe, M | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study[NCT00088452] | Phase 3 | 453 participants (Actual) | Interventional | 2004-07-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Number of Participants With Attention Deficit as Measured by the Confidence Index of the CPT-II and the K-CPT
A Confidence Index of 0.60 or higher on the Conners' Continuous Performance Test at the visit at 16 or 20 weeks or at an earlier visit when treatment was discontinued (as long as the discontinuation occurred 1 month or more after the baseline visit and was not due to intolerable adverse events). A Confidence Index of 0.60 corresponds to a 60% probability that the child has clinical attention deficit disorder. (NCT00088452)
Timeframe: First 16-20 weeks of double blind therapy
| Intervention | Participants (Count of Participants) |
|---|
| Ethosuximide | 35 |
| Lamotrigine | 25 |
| Valproic Acid | 52 |
Number of Participants With Freedom From Treatment Failure at 12 Months of Double Blind Therapy
Treatment failure was defined as persistence of absence seizures at 12 months of double blind therapy, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician. (NCT00088452)
Timeframe: First 12 months of double blind therapy
| Intervention | Participants (Count of Participants) |
|---|
| Ethosuximide | 70 |
| Lamotrigine | 31 |
| Valproic Acid | 64 |
Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy
Treatment failure was defined as persistence of absence seizures at week 16 or week 20, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician. (NCT00088452)
Timeframe: First 16-20 weeks of double blind therapy
| Intervention | Participants (Count of Participants) |
|---|
| Ethosuximide | 81 |
| Lamotrigine | 43 |
| Valproic Acid | 85 |
Trials
2 trials available for lamotrigine and Attention Deficit and Disruptive Behavioral Disorders